Ivonescimab (NCT06925724)

Name: Ivonescimab trial for Endometrial Cancer (NCT06925724)
Uploaded: 2026-10-31T15:19:52.902Z
Duration: 1 min 8 s
Description: Ivonescimab trial for Endometrial Cancer (NCT06925724). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06925724.

A Study of Ivonescimab in People With Endometrial and Cervical Cancers: a one-minute explainerNCT069257241 min

Ivonescimab trial for Endometrial Cancer (NCT06925724). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with recurrent or metastatic endometrial or cervical cancer that progressed after at least one platinum-based regimen. Previous PD-1 or VEGF treatment is allowed; eligible tissue types are specified.

The idea: give ivonescimab infusions every three weeks for up to two years. This antibody blocks PD-1 to support immune attack and VEGF to restrict tumor blood-vessel growth. Researchers measure responses and safety. Tumor profiling data or tissue for profiling is required.

This phase 2 study plans 50 patients. Maria Rubinstein leads Memorial Sloan Kettering's seven recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.